References
1. Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, et
al. The oncologic burden of hepatitis C virus infection: A clinical
perspective. CA: a cancer journal for clinicians. 2017;67(5):411–31.
2. Garrison KL, German P, Mogalian E, Mathias A. The Drug-Drug
Interaction Potential of Antiviral Agents for the Treatment of Chronic
Hepatitis C Infection. Drug Metabolism and Disposition.
2018;46(8):1212–25.
3. Hamilton G, Rath B, Burghuber O. Pharmacokinetics of crizotinib in
NSCLC patients. Expert Opinion on Drug Metabolism & Toxicology.
2015;11(5):835–42.
4. Drilon A, Clark JW, Weiss J, Ou S-HI, Camidge DR, Solomon BJ, et al.
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14
alteration. Nature Medicine. 2020;26(1):47–51.
5. Pfizer. Xalkori (crizotinib) 250 mg, hard capsules, Summary of
product characteristics (SmPC). Pfizer Europe MA EEIG, Belgium (2012 rev
23/10/2018).
6. Tartarone A, Gallucci G, Lazzari C, Lerose R, Lombardi L, Aieta M.
Crizotinib-induced cardiotoxicity: the importance of a proactive
monitoring and management. Future Oncology. 2015;11(14):2043–8.
7. Yu H, Steeghs N, Nijenhuis CM, Schellens JHM, Beijnen JH, Huitema
ADR. Practical Guidelines for Therapeutic Drug Monitoring of Anticancer
Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets.
Clinical Pharmacokinetics. 2014;53(4):305–25.
8. Smolders EJ, Jansen AME, ter Horst PGJ, Rockstroh J, Back DJ, Burger
DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic
Considerations: A 2019 Update. Clin Pharmacokinet. 2019
Oct;58(10):1237–63.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al.
A method for estimating the probability of adverse drug reactions.
Clinical Pharmacology and Therapeutics. 1981;30(2):239–45.
10. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al.
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).
Pharmacogenetics and Genomics. 2011;21(3):152–61.
11. Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli
S. Assessment of antihypertensive compliance using a self-administered
questionnaire: development and use in a hypertension clinic. Presse Med.
2001 Jun 16;30(21):1044–8.
12. Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J, et
al. Use of Multiple Probes to Assess Transporter- and Cytochrome
P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV
NS5A Inhibitor Velpatasvir. Clinical Pharmacokinetics.
2016;55(5):605–13.
13. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its
advantages over the proportional reporting ratio. Pharmacoepidemiology
and Drug Safety. 2004;13(8):519–23.
14. Mir O, Blanchet B, Goldwasser F. Drug-Induced Effects on Erlotinib
Metabolism. New England Journal of Medicine. 2011;365(4):379–80.
15. Hong J, Wright RC, Partovi N, Yoshida EM, Hussaini T. Review of
Clinically Relevant Drug Interactions with Next Generation Hepatitis C
Direct-acting Antiviral Agents. Journal of Clinical and Translational
Hepatology. 2020 Sep 28;8(3):1–14.